Ximelagatran: the first oral direct thrombin inhibitor

Bibliography

• OWEN CA Jr, BOWIE EJ: The History of the Development of Oral Anticoagulant Drugs. In: Oral Anticoagulants. L Poller, J Hirsh (Eds) Oxford University Press, New York, USA (1996):1–8.
   Google Scholar
• LANDEFELD CS, ROSENBLATT MW, GOLDMAN L: Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am. J. Med. (1989) 87(2):153–159.
   PubMed Web of Science ®Google Scholar
• HYLEK EM, GO AS, CHANG Y et al: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl. I Med. (2003) 349(11):1019–1026.
   PubMed Web of Science ®Google Scholar
• SCORDO MG, PENGO V, SPINA E, DAHL ML, GUSELLA M, PADRINI R: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Phannacol Ther. (2002) 72(6):702–710.
   PubMed Web of Science ®Google Scholar
• WELLS PS, HOLBROOK AM, CROWTHER NR, HIRSH J: Interactions of warfarin with drugs and food. Ann. Intern. Med. (1994) 121(9):676–683.
   PubMed Web of Science ®Google Scholar
• MANN KG, BUTENAS S, BRUMMEL K: The dynamics of thrombin formation. Ade/lose/ff. a/MA V3SC. Biol. (2003) 23(1):17–25.
   Google Scholar
• •An excellent overview of blood coagulation with a focus on thrombin.
   Google Scholar
• WALSH PN: Roles of factors XI, platelets and tissue factor-initiated blood coagulation. J. Thromb. Haemost. (2003) 1(10):2081–2086.
   PubMed Web of Science ®Google Scholar
• SAMBRANO GR, WEISS EJ, ZHENG YW, HUANG W, COUGHLIN SR: Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature (2001) 413(6851):74–78.
   PubMed Web of Science ®Google Scholar
• PATTERSON C, STOUFFER GA, MADAMANCHI N, RUNGE MS: New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ. Res. (2001) 88(10):987–997.
   PubMed Web of Science ®Google Scholar
• WEITZ JI, BULLER HR: Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation (2002) 105(8):1004–1011.
   PubMed Web of Science ®Google Scholar
• ••A detailed review of direct thrombininhibitors.
   Google Scholar
• HIRSH J: Heparin. N Engl. I Med. (1991) 324(26):1565–1574.
   PubMedGoogle Scholar
• WEITZ JI: Low-molecular-weight heparins. N Engl. J. Med. (1997) 337(10):688–698.
   PubMed Web of Science ®Google Scholar
• EITZMAN DT, CHI L, SAGGIN L, SCHWARTZ RS, LUCCHESI BR, FAY WP: Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation (1994) 89 (4) :1523–1529.
   Google Scholar
• AREPALLY G, CINES DB: Pathogenesis of heparin-induced thrombocytopenia and thrombosis. Autoinonun Rev (2002) 1(3):125–132. Expert Op/n. Investig. Drugs (2004) 13(4)411
   Google Scholar
• REZAIE AR: P rothrombin protects Factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood (2001) 97(8):2308–2313.
   PubMed Web of Science ®Google Scholar
• BRUFATTO N, NESHEIM ME: The use of prothrombin (S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation. j. Biol. Chem. (2001) 276(21):17663–17671.
   PubMed Web of Science ®Google Scholar
• HOGG PJ, JACKSON CM: Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc. Natl. Acad. Sci. USA (1989) 86(10):3619–3623.
   PubMed Web of Science ®Google Scholar
• WEITZ JI, HUDOBA M, MASSEL D, MARAGANORE J, HIRSH J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. I Clin. Invest. (1990) 86(2):385–391.
   PubMed Web of Science ®Google Scholar
• EISENBERG PR, SIEGEL JE, ABENDSCHEIN DR, MILETICH JP: Importance of Factor Xa in determining the procoagulant activity of whole-blood clots. Clin. Invest. (1993) 91(5):1877–1883.
   Google Scholar
• MUTCH NJ, ROBBIE LA, BOOTH NA: Human thrombi contain an abundance of active thrombin. Thromb. Haemost. (2001) 86(4):1028–1034.
   PubMed Web of Science ®Google Scholar
• WEITZ JI, LESLIE B, HUDOBA M: Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation (1998) 97(6):544–552.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BI, EKMAN S, LINDBRATT S et al: Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. Bone John Surg. Am. (1997) 79(3):326–333.
   Google Scholar
• ERIKSSON BI, WILLE-JORGENSEN P, KALEBO P et al: A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl. Med. (1997) 337(19):1329–1335.
   PubMed Web of Science ®Google Scholar
• DIRECT THROMBIN INHIBITOR TRIALISTS' COLLABORATIVE GROUP: Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet (2002) 359(9303):294–302.
   PubMed Web of Science ®Google Scholar
• KELLER C, MATZDORFF AC, KEMKES-MATTHES B: Pharmacology of warfarin and clinical implications. Semin. Thromb. Hemost. (1999) 25(1):13–16.
   PubMed Web of Science ®Google Scholar
• GINSBERG JS: Management of venous thromboembolism. N Engl. Med. (1996) 335(24):1816–1828.
   PubMedGoogle Scholar
• GO AS, HYLEK EM, BOROWSKY LH, PHILLIPS KA, SELBY JV, SINGER DE: Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann. Intern. Med. (1999) 131(12):927–934.
   PubMed Web of Science ®Google Scholar
• SAMSA GP, MATCHAR DB, GOLDSTEIN LB et al: Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch. Intern. Med. (2000) 160(7):967–973.
   PubMed Web of Science ®Google Scholar
• GUSTAFSSON D, ELG M: The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb. Res. (2003) 109 (Suppl. 1):59–515.
   Google Scholar
• ••A detailed overview of the pharmacologyof ximelagatran.
   Google Scholar
• JOHANSSON LC, ANDERSON M, FABER G, GUSTAFSSON D, ERIKSSON UG: No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin. Pharmacokinet. (2003) 42(5):475–484.
   PubMed Web of Science ®Google Scholar
• SARICH TC, TENG R, PETERS GR et al.: No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Pharmacokinet. (2003) 42(5):485–492.
   PubMed Web of Science ®Google Scholar
• WAHLANDER K, ERIKSSON-LEPKOWSKA M, FRISON L, FAGER G, ERIKSSON UG: No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin. Pharmacokinet. (2003) 42(8):755–764.
   PubMed Web of Science ®Google Scholar
• JOHANSSON LC, FRISON L, LOGREN U, FAGER G, GUSTAFSSON D, ERIKSSON UG: Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin. Pharmacokinet. (2003) 42(4):381–392.
   PubMed Web of Science ®Google Scholar
• FAGER G, CULLBERG M, ERIKSSON-LEPKOWSKA M, FRISON L, ERIKSSON UG: Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Eui: Clin. Pharmacol (2003) 59(4):283–289.
   PubMed Web of Science ®Google Scholar
• BREDBERG E, ANDERSSON TB, FRISON L et al.: Ximelagatran, an oral direct thrombin inhibitor, has low potential for cytochrome P450-mediated drug-drug interactions. Clin. Pharmacokinet. (2003) 42(8):765–777.
   PubMed Web of Science ®Google Scholar
• ELG M, BORJESSON I, PEHRSSON S et al.: Feiba reversed bleeding times prolonged by high doses of a thrombin inhibitor and was not prothrombotic. Blood (2000) 96(11) (Abstract).
   Google Scholar
• ULVINGE J-C, BERNTSSON P, BOSTROM SL: Melagatran-induced inhibition of thrombin generation is reversed by Feiba. Blood (2000) 96(11) (Abstract).
   Google Scholar
• ERIKSSON BI, BERGQVIST D, KALEBO P et al.: Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomized trial. Lancet (2002) 360(9344):1441–1447.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BI, AGNELLI G, COHEN AT et al.: METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee joint replacement. The METHRO III study. Thromb. Haemost. (2003) 89(2):288–296.
   Google Scholar
• ERIKSSON BI, AGNELLI G, COHEN AT et al.: EXPRESS Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb. Haemost. (2003) 1(12):2490–2496.
   Google Scholar
• COLWELL CW, BERKOWITZ SD, DAVIDSON BL et al.: Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb. Haemost. (2003) 1(10):2119–2130.
   PubMed Web of Science ®Google Scholar
• FRANCIS CW, DAVIDSON BL, BERKOWITZ SD et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann. Intern. Med. (2002) 137(8):648–655.
   PubMed Web of Science ®Google Scholar
• FRANCIS CW, BERKOWITZ SD, COMP PC et al: EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl. I Med. (2003) 349(18):1703–1712.
   Google Scholar
• COLWELL CW, BERKOWITZ SD, COMP PC et al: EXULT B Investigators. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B. Blood (2003) 102(11):14 (Abstract).
   Google Scholar
• ERIKSSON H, WAHLANDER K, GUSTAFSSON D, WELIN LT, FRISON L, SCHULMAN S: THRIVE Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb. Haemost. (2003) 1(1):41–47.
   Google Scholar
• FRANCIS CW, GINSBERG JS, BERKOWITZ SD et al.: THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: The THRIVE treatment study. Blood (2003) 102(11):6 (Abstract).
   Google Scholar
• SCHULMAN S, WAHLANDER K, LUNDSTROM T, CLASON SB, ERIKSSON H: THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl. J. Med. (2003) 349(18):1713–1721.
   Google Scholar
• ••This study compares ximelagatran withplacebo and shows the efficacy and safety of the drug.
   Google Scholar
• PETERSEN P, GRIND M, ADLER J: SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J. Am. Coll. Cardiol (2003) 41(9):1445–1451.
   Google Scholar
• PETERSEN P: A long-term follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Blood (2001) 98:2953 (Abstract).
   Google Scholar
• HALPERIN JL: Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am. Heart .1. (2003) 146(3):431–438.
   Google Scholar
• WALLENTIN L, WILCOX RG, WEAVER WD et al: ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet (2003) 362(9386):789–797.
   Google Scholar
• HELLGREN M, JOHANSSON S, ERIKSSON UG, WAHLANDER K: Excretion of the oral direct thrombin inhibitor ximelagatran into breast milk following oral administration to breastfeeding women. J Thromb. Haemost. (2003) (Suppl. 1) (Abstract). Affiliation Mark A Crowther MD, MSc, FRCPC & Jeffrey I Weitzjr MD, FRCPC -rAuthor for correspondence Henderson Research Centre, 711 Concession Street, Hamilton, Ontario, L8V 1C3, Canada Tel: +1 905 574 8550; Fax: +1 905 575 2646; E-mail: [email protected]
   Google Scholar